Currently, subjective measures of disease activity, such as the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) or the global opinion of the physician, are most important in the evaluation of TNF-α blocking therapy in AS. This evidence concerns the gene TNF and ankylosing spondylitis.